Despite reports that Pfizer is now the front-runner to snap up cancer biotech Medivation, its original suitor Sanofi is confident that its low ball $9.3 billion offer will be accepted after filing under the Hart-Scott-Rodino Antitrust Improvements Act.
This move, which happens when a company believes it is about to subsume another company, shows Sanofi’s bullishness in getting the deal done–despite the fact that it was roundly rejected by Medivation just weeks’ ago and comes amid swirling rumors that it has opened talks with Pfizer.
Sanofi has in the past week hinted at both potentially extending its offer–but also going hostile if the Xtandi producer’s board doesn’t play ball.
In a brief statement, the French drugmaker–which is looking to beef up its relatively weak and until recently half abandoned oncology pipeline–said: “As announced on April 28, 2016, Sanofi proposed to acquire Medivation for $52.50 per share, representing an all-cash transaction valued at approximately $9.3 billion”–indicating it is not yet willing to budge on price.
Analysts have said the biotech could fetch as much as $70 a share, with Novartis, AstraZeneca and Amgen also all said to be circling.
By Ben Adams
Source: Fierce Biotech
Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.
On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.
General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.